HealthDay - SUNDAY, Sept. 25 (HealthDay News) -- The bone drug Zometa, once considered a promising weapon to reduce the risk of breast cancer recurrence, should not be used routinely in treatment of the disease, researchers say.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.